Get started
Author

Hadir M. Emara

Observed name: Hadir Emara
ORCID: 0009-0007-1820-9979
Observed ORCID: 0009-0007-1820-9979
OpenAlex ID: A5095754373
A comprehensive review on targeted therapies for triple negative breast cancer: an evidence-based treatment guideline
2025 · Hadir M. Emara, Nageh K. Allam, et al. · Discover Oncology · 23
PDF
MIAT: A pivotal oncogenic long noncoding RNA tunning the hallmarks of solid malignancies
2025 · Monica M. Rostom, Alaa A. Rashwan, et al. · Translational Oncology · 9
Electrochemical biosensors for vancomycin monitoring in blood: advances, strategies, and future perspectives
2025 · Aya M. Gaber, Hadir M. Emara, et al. · RSC Advances · 5
PDF
Advances in Nanotechnology for Drug Delivery Modulation in Neurodegenerative Diseases
2024 · Dania Abdel-Dayem, Hadir Emara, et al. · Springer eBooks · 2
Clinically validated self-assembled nanoparticles for precision oncology: Drug chemistry-guided design and scalable translation
2026 · Hadir M. Emara, Ahmad M. Mohammad, et al. · Journal of Drug Delivery Science and Technology · 1
Low-dose DOX–polygodial nanosystem modulates the CD47/CALR axis for safer triple negative breast cancer treatment
2026 · Hadir M. Emara, Rana A. Youness, et al. · Nanoscale Advances · 1
PDF
Mechanism-based precision pharmacology of natural products for triple-negative breast cancer: translational opportunities for targeted therapeutics
2026 · Hadir M. Emara, Nageh K. Allam · RSC Medicinal Chemistry
Advances in Nanotechnology for Drug Delivery Modulation in Neurodegenerative Diseases
2023 · Dania Abdel-Dayem, Hadir Emara, et al. · Springer eBooks
Works count: 8
Citation count: 41
H-index: 3
I10-index: 1
Year
Topic
Type